Ariad announces updated Phase I/II results on brigatinib

Ariad Pharmaceuticals (Nasdaq: ARIA) has announced updated Phase I/II clinical data on its investigational tyrosine kinase inhibitor brigatinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.

The results show robust anti-tumor activity of brigatinib in patients with crizotinib-resistant ALK+ non-small cell lung cancer in 98 patients treated at doses of 90 mg/day for one week followed by escalation to 180 mg/day in the Phase II portion. These responses are now approaching one year.

Of the 79 ALK+ non-small cell lung cancer patients in the trial, 49 of them also had intracranial CNS metastases at baseline. The effect on the metastases was evaluated separately, and this review showed that 16 had measurable intracranial metastases and 33 had non-measurable metastases.